A table summarizing the dosages for definitive and symptom control in acute diarrhea in children, based on the 2019 Thai Clinical Practice Guideline, focusing on the interventions we've discussed:
Intervention | Dosage | Duration | Indications | Notes |
Rehydration | ||||
Reduced Osmolality ORS (RO-ORS) | * Mild Dehydration: 50 ml/kg over 4 hours * Moderate Dehydration: 100 ml/kg over 4 hours * Ongoing Losses (Vomiting): 5 ml/kg per vomiting episode * Ongoing Losses (Diarrhea): 10 ml/kg per diarrhea episode * Maximum per Episode: 240 ml (for the first 1-3 days) | As needed | Mild to moderate dehydration | Give small, frequent amounts to minimize vomiting |
IV Normal Saline or Lactated Ringer's | 20 ml/kg over 10-15 minutes (repeat as needed) | Severe dehydration or shock | ||
IV D5NSS or D5NSS/2 | Based on serum sodium and fluid needs | Maintenance IV fluids after initial rehydration | ||
IV Potassium Chloride | 20 mmol/L added to IV fluids (not exceeding 0.5 mmol/kg/hour) | Once urine output is good | ||
Symptom Control | ||||
Racecadotril | 1.5 mg/kg/dose, three times daily | 3-5 days | Diarrhea (for children 3 months and older) | May help reduce stool volume and shorten diarrhea duration |
Diosmectite | 6-9 g/day divided 2-3 times daily | 3-5 days | Diarrhea (for children 2 years and older) | May help reduce diarrhea duration; give at least 1 hour apart from other medications |
Ondansetron | 0.1-0.2 mg/kg/dose (max 8 mg), single dose, IV or oral OR * 2 mg oral dose (weight 7-15 kg) * 4 mg oral dose (weight 15-30 kg) * 6 mg oral dose (weight > 30 kg) | Single dose | Vomiting (for children 6 months and older) | |
Definitive Control (Select Cases) | ||||
Zinc | 20 mg/day | 10-14 days | Suspected zinc deficiency or malnutrition (for children older than 6 months) | |
Antibiotics | Refer to Tables 4 & 5 in the guideline | 3-10 days (depending on antibiotic and pathogen) | Confirmed bacterial pathogens or suspected invasive bacterial infection/sepsis | Selection and dosage based on specific pathogen and local resistance patterns |
Key Points
Always prioritize rehydration.
RO-ORS is the first-line treatment for dehydration.
Use frequent, small amounts of ORS for vomiting and ongoing diarrhea losses.
Do not routinely use antibiotics.
Consider probiotics for acute watery diarrhea in immunocompetent children.
Zinc supplementation is only for children with suspected zinc deficiency or malnutrition.
Disclaimer: This table is a summary and does not replace the complete 2019 Thai Clinical Practice Guideline. Always consult the full guideline for comprehensive management recommendations.
Introduction
Acute diarrhea in children is a global health challenge, demanding a meticulous approach to diagnosis and management. This article, meticulously crafted from the 2019 Thai Clinical Practice Guideline for Acute Diarrhea in Children, serves as a definitive guide for pediatric residents, providing detailed information on etiology, pathophysiology, clinical presentation, diagnosis, treatment, and prevention.
Epidemiology and Definitions
Acute diarrhea, defined as three or more loose or liquid stools per day, remains a major cause of childhood illness in Thailand, with an incidence of approximately 1,850 per 100,000 population. While mortality rates have declined, the impact on child health and family well-being remains significant.
Diarrhea is categorized based on duration:
Acute: Less than 7 days.
Prolonged: 8-13 days.
Persistent or Chronic: 14 days or more.
Etiology
Infectious agents are the leading cause of acute diarrhea in children.
Viruses: Rotavirus, Norovirus, Adenovirus (types 40/41), Astrovirus, Sapovirus.
Bacteria: Vibrio cholerae, Diarrheagenic Escherichia coli (DEC), Campylobacter spp., Salmonella spp., Shigella spp., Clostridioides difficile.
Protozoa: Giardia lamblia, Entamoeba histolytica, Cryptosporidium spp.
Non-infectious causes include antibiotic-associated diarrhea, food intolerances, and medication side effects.
Pathophysiology
The mechanisms behind diarrhea are diverse and pathogen-dependent:
Osmotic: Unabsorbed substances in the gut lumen draw water in, as in lactose intolerance.
Secretory: Bacterial enterotoxins trigger fluid secretion from intestinal cells.
Inflammatory: Pathogen invasion damages the intestinal lining, causing inflammation and fluid loss.
Motility: Altered intestinal transit, often from viral infections, reduces fluid absorption.
Clinical Features and Diagnosis
The diagnosis of acute diarrhea is primarily clinical, based on history and physical examination.
History: Onset and duration of diarrhea, stool frequency and consistency, blood or mucus in stools, associated symptoms (abdominal pain, vomiting, fever, tenesmus), dietary history, travel history, antibiotic use, exposure to ill individuals.
Physical Exam: Vital signs, dehydration assessment, abdominal examination.
Laboratory testing is guided by clinical suspicion and severity:
Stool: Microscopy, culture, viral antigen testing, PCR (especially in prolonged cases).
Blood: CBC, electrolytes, BUN, creatinine, blood culture (if sepsis is suspected).
Dehydration Assessment
Accurate dehydration assessment is critical to guide management.
Percentage of body weight lost: Provides the most precise measure but often unavailable.
Clinical evaluation using:
WHO Dehydration Scale: Assesses for specific signs like thirst, restlessness, sunken eyes, and skin pinch.
CDC Dehydration Scale: Evaluates a broader range of signs, including mental status, heart rate, pulse quality, and urine output.
Management
1. Rehydration
Oral Rehydration Therapy (ORT): The mainstay of treatment for mild to moderate dehydration.
Reduced Osmolality ORS (RO-ORS): The preferred choice due to improved tolerability.
Dosage:
Mild Dehydration: 50 ml/kg over 4 hours.
Moderate Dehydration: 100 ml/kg over 4 hours.
Ongoing Losses:
Vomiting: 5 ml/kg per vomiting episode.
Diarrhea: 10 ml/kg per diarrhea episode.
Maximum: 240 ml per episode for the first 1-3 days.
Administration: Give small, frequent amounts, using a spoon or syringe, to minimize vomiting.
Intravenous Rehydration Therapy (IVRT): Indicated for severe dehydration, shock, or failure of ORT.
Fluid Selection:
Initial bolus for shock: Normal saline or lactated Ringer's, 20 ml/kg over 10-15 minutes (repeat as needed).
Subsequent IV fluids: D5NSS or D5NSS/2 based on serum sodium.
Potassium chloride: 20 mmol/L added to IV fluids once urine output is good (not exceeding 0.5 mmol/kg/hour).
2. Nutritional Management
Breastfeeding: Encourage continuation throughout the illness.
Formula-fed infants: Resume age-appropriate formula after rehydration, without diluting.
Lactose-free formula: May be considered in non-breastfed infants with severe diarrhea or suspected lactose intolerance.
Solid foods: Offer age-appropriate, easily digestible foods in small, frequent amounts as tolerated. Avoid high-sugar drinks.
3. Pharmacological Therapy
Antidiarrheal medications:
Racecadotril: 1.5 mg/kg/dose, three times daily, for 3-5 days (for children 3 months and older).
Diosmectite: 6-9 g/day divided 2-3 times daily for 3-5 days (for children 2 years and older). Give at least 1 hour apart from other medications.
Antiemetics:
Ondansetron: 0.1-0.2 mg/kg/dose (maximum 8 mg) as a single dose, orally or IV, for children 6 months and older. Alternatively, use weight-based oral dosing:
2 mg for 7-15 kg
4 mg for 15-30 kg
6 mg for > 30 kg
Probiotics:
Lactobacillus rhamnosus GG: > 1010 CFU/day for 5-7 days.
Saccharomyces boulardii: 250-750 mg/day for 5-7 days.
Lactobacillus reuteri DSM 17938: 108 - 2 x 108 CFU/day for 5-7 days.
Note: Avoid probiotics in immunocompromised children.
Zinc supplementation:
Dosage: 20 mg/day for 10-14 days, only for children over 6 months with malnutrition or suspected zinc deficiency.
4. Antibiotics
Not routinely recommended.
Indications:
Confirmed bacterial pathogens based on culture or clinical suspicion.
Empirical therapy for suspected invasive bacterial infection or sepsis.
Specific antibiotics and dosages: Refer to Tables 4 and 5 in the guideline for detailed recommendations tailored to the specific pathogen and severity of the infection. Local resistance patterns should guide antibiotic selection.
5. Prevention
Rotavirus vaccination.
Breastfeeding for at least 6 months.
Handwashing with soap and water.
Access to safe drinking water.
Conclusion
Acute diarrhea in children requires a comprehensive approach to assessment and management. By adhering to the recommendations outlined in the 2019 Thai Clinical Practice Guideline, pediatric residents can confidently diagnose, treat, and prevent acute diarrhea, ultimately reducing its impact on children and families.
And what about Bioplore
Bioplore (Diosmectite) - Beyond Watery Diarrhea?
The guideline recommends Bioplore as an adjunctive therapy to ORS in children 2 years and older with acute watery diarrhea, citing evidence for its effectiveness in reducing diarrhea duration. While not explicitly stated, Bioplore's properties might extend its usefulness to scenarios where reducing stool volume is desired, even without typical watery diarrhea.
Mechanism of Action:
Bioplore is a natural hydrated aluminomagnesium silicate with unique properties:
Mucoprotective: It binds to the mucus layer of the gastrointestinal tract, enhancing its protective barrier function. This strengthened barrier can help prevent further fluid loss and soothe irritated intestinal mucosa.
Adsorbent: It can bind to various substances, including toxins produced by bacteria and viruses, reducing their harmful effects on the gut.
Anti-inflammatory: Studies suggest it can reduce intestinal inflammation, contributing to the healing of the gut lining.
Potential Benefits in Reducing Stool Volume:
While research primarily focuses on watery diarrhea, Bioplore's actions could contribute to reducing stool volume in other situations:
Increased Water Absorption: By enhancing the mucus barrier and reducing inflammation, Bioplore could promote better water reabsorption in the large intestine, even if the stool isn't primarily watery.
Toxin Binding: Binding and neutralizing toxins could decrease their irritant effect on the gut, potentially leading to less fluid secretion and reduced stool volume.
Improved Motility: While not a direct effect, reduced inflammation and toxin burden could contribute to improved intestinal motility, leading to more formed stools.
Considerations:
Limited Evidence: The guideline doesn't provide specific recommendations for using Bioplore to reduce stool volume in the absence of watery diarrhea. Further research is needed to establish its efficacy in such scenarios.
Individualized Approach: The decision to use Bioplore in non-watery diarrhea should be made on a case-by-case basis, considering the child's age, clinical presentation, and potential benefits and risks.
Dosage: If using Bioplore for this purpose, the recommended dosage of 6-9 g/day divided 2-3 times daily, for 3-5 days, can be considered. However, consulting with a pediatric gastroenterologist is advisable.
Incorporating Bioplore's Potential:
When crafting a comprehensive article based on the guideline, acknowledging Bioplore's potential role in reducing stool volume, even in non-watery diarrhea, can be valuable. Here's how you can incorporate it:
Under the "Pharmacological Therapy" section: After discussing Bioplore's use in acute watery diarrhea, add a paragraph addressing its potential in other scenarios:
"Although primarily recommended for watery diarrhea, Bioplore's mucoprotective, adsorbent, and anti-inflammatory properties might also be beneficial in reducing stool volume in situations where the stool is not primarily watery. This could be particularly relevant in cases where reducing the frequency or volume of bowel movements is desired for the child's comfort. However, further research is needed to confirm its efficacy in such scenarios, and clinicians should consider the potential benefits and risks on a case-by-case basis."
By including this information, you provide a more nuanced perspective on Bioplore's potential applications, enhancing the guideline's practical value for pediatric residents encountering diverse presentations of diarrhea. Remember to emphasize the need for individualized assessment and clinical judgment, and consider consulting with a pediatric gastroenterologist when appropriate.
Comentários